In September revenues increased by 30%, substantial increase in all major markets


JSC Olainfarm preliminary consolidated results for September 2019 indicate that revenues increased by 30% compared to the same month last year and reached 12.4 million euro. At the same time consolidated results for the first nine months of 2019 show that revenues reached 98.8 million euro which is an increase by 11%, compared to the nine-month period of 2018. Extraordinary rapid increase in sales was in Ukraine, Kazakhstan and Uzbekistan markets. Products of Olainfarm Group during this period were sold in 54 markets worldwide.

Consolidated sales in September show revenue increase in all of the main markets. In Russia sales grew by 21%, in Latvia by 9%, in Belarus by 67%, in Ukraine by 137%, in Kazakhstan by 823%, in Moldova by 46%, in Uzbekistan by 542%, in Lithuania by 63% and in Poland by 45%. Brazil was among the largest markets where products were sold in amount of 151 thousand EUR.

In the nine months of 2019, the main sales markets of Olainfarm Group continued to contribute 78% of the total revenue – Latvia’s  and Russia’s share was 28%, Belarus (12% share) and Ukraine (8% share). Other major sales markets included Kazakhstan, Uzbekistan, the Netherlands, Germany, Tajikistan and Italy. The most rapid sales growth during this nine-month period was achieved in the Netherlands, where sales grew by 188% compared to the last year, and in Uzbekistan where sales grew by 50%. Sales in Russia improved by 10%, in Latvia by 12%, in Belarus by 9%, in Kazakhstan by 13%, in Tajikistan by 18% but in Italy by 40%. Amongst the largest sales outlets a decline was marked in Ukraine (-1%).

JSC "Olainfarm" continues to show strong sales results by increasing sales in all major markets in September. We are also expanding our cooperation with new foreign partners, such as those from Egypt and Brazil. Deliveries of the anti-tuberculosis drug PASS sodium will continue in October, according to the contract. With the aim of strengthening both production and export capacity, we are expanding our manufacturing facility, acquiring new equipment, and strengthening the company’s marketing team by attracting a professional with long-standing experience, “says Lauris Macijevskis, Chairman of the Management Board of JSC Olainfarm.

September 2019, consolidated sales   Sales, thous. EUR Share in total sales Changes to September 2018
Russia 4 841 39% 21%
Latvia 3 212 26% 9%
Belarus 1 168 9% 67%
Ukraine 808 7% 137%
Kazakhstan 391 3% 823%
Moldova 207 2% 46%
Uzbekistan 182 1% 542%
Lithuania 165 1% 63%
Poland 163 1% 45%
Brazil 151 1% N/A
Other 1 115 9% 0%
Total 12 404 100% 30%

9 months 2019, consolidated sales Sales, thous. EUR Share in total sales Changes to 9 months 2018
Russia 28 973 29% 10%
Latvia 28 375 29% 12%
Belarus 11 906 12% 9%
Ukraine 8 121 8% -1%
Kazakhstan 2 555 3% 13%
Uzbekistan 2 427 2% 50%
Netherlands 1 802 2% 188%
Germany 1 498 2% 4%
Tajikistan 1 267 1% 18%
Italy 1 102 1% 40%
Other 10 769 11% 4%
Total 98 797 100% 11%

Unconsolidated sales – September and 9 months

According to preliminary unconsolidated figures, JSC Olainfarm sales reached 9.5 million euros in September, which represents an increase by 37% compared to September, 2018. Sale of products improved in Russia (+27%), Latvia (+16%), Belarus (+9%), Ukraine (+95%), Kazakhstan (+736%), Uzbekistan (+542%) and Mongolia (722%). Active pharmaceutical ingredients were sold to clients in Brazil, Egypt and India.

The unconsolidated sales results for the first nine months of 2019 show that JSC Olainfarm sales reached 75 million euros, which represents an increase by 11% compared to the first nine months of 2018. During this reporting period, sales have increased in nine out of the ten major markets of Olainfarm – Russia (+16%), Latvia (+4%), Belarus (+6%), Uzbekistan (+50%), the Netherlands (+189%), Kazakhstan (+1%), Germany (+4%), Tajikistan (+16%) and in Italy (+47%). Revenues declined by 2% in Ukraine.

September 2019, unconsolidated sales Sales, thous. EUR Share in total sales Changes to September 2018
Russia 4 476 47% 27%
Latvia 1 534 16% 13%
Belarus 887 9% 76%
Ukraine 663 7% 95%
Kazakhstan 354 4% 736%
Uzbekistan 182 2% 542%
Brazil 151 2% N/A
Egypt 142 1% N/A
India 133 1% N/A
Mongolia 129 1% 722%
Other 873 9% -22%
Total 9 523 100% 37%

Nine months 2019 unconsolidated sales Sales, thous. EUR Share in total sales Changes to nine months 2018
Russia 26 390 35% 16%
Latvia 12 901 17% 4%
Belarus 9 638 13% 6%
Ukraine 7 856 10% -2%
Uzbekistan 2 427 3% 50%
The Netherlands 1 802 2% 189%
Kazakhstan 1 550 2% 1%
Germany 1 487 2% 4%
Tajikistan 1 215 2% 16%
Italy 1 102 1% 47%
Other 8 554 11% 4%
Total 74 923 100% 11%

Results of subsidiaries – September and the first nine months of 2019

The pharmacy chain SIA Latvijas Aptieka sales reached 2.2 million euros in September 2019, which represents a 11% increase compared to September 2018. 68 pharmacies were operating during this period. SIA Silvanols sales reached 0.6 million euros in September 2019, representing an increase by 4% vs. September 2018. The combined sales of Tonus Elast and Elast Medical in September 2019 were 0.8 million euros, which is by 1% less than this time last year. Olainmed and Diamed Medical Center sales reached 0.27 million euros, while the Belarus subsidiary NPK Biotest reached 0.28 million euros in sales in September that is higher by 43% than in September last year.

During the first nine month period of 2019, SIA Latvijas Aptieka sales amounted to 19.2 million euros, demonstrating an 8% increase in comparison to the same time period last year. Sales of SIA Silvanols reached 4.2 million euros which is 2% less than last year. The combined sales of Tonus Elast and Elast Medical during nine months this year totaled 7.1 million euros which is an increase by 1%. Medical Centers Diamed and Olainmed revenues were 2.3 million euros during the first nine months of this year and the Belarus company NPK Biotest sales were worth 2.3 million euros, improving the result of the last year by 33%.

  September 2019 9 months 2019
Sales markets of Olainfarm 33 45
Sales markets of the Group 38 54
Number of pharmacies 68  
Sales of Latvijas Aptieka, thous. EUR 2 167 19 199
Sales of Medical centers, thous. EUR 264 2 316
Sales of NPK Biotest, thous. EUR 281 2 258
Sales of Tonus Elast and Elast Medical, thous. EUR 833 7 138
Sales of Silvanols, thous. EUR 607 4 179

According to the JSC Olainfarm budget, unconsolidated sales are planned to reach 99 million euros in 2019, while consolidated sales are expected at 133 million euros.  According to these preliminary sales figures, in the first nine months of 2019, 76% of annual target for unconsolidated sales and 74% of annual target for consolidated sales have been reached.

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top -quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 60 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Additional information:
Jānis Dubrovskis
Investor Relations Advisor of JSC Olainfarm
Phone: +371 29178878

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Orange Belgium and Proximus signed today the agreement to establish their mobile access network sharing collaboration22.11.2019 18:18:00 CETPress release

Joint press release 22 November 2019 Orange Belgium and Proximus signed today the agreement to establish their mobile access network sharing collaboration Michaël Trabbia, CEO of Orange Belgium, and Sandrine Dufour, CEO ad Interim of Proximus, signed today the final agreements to establish the previously announced mobile access network sharing collaboration. Brussels – The shared mobile access network will be designed, built and operated by a new joint venture, owned 50/50 by Orange Belgium and Proximus, which will be based in Brussels. Each party confirms its respective expected benefits and investment as per complementary information for investors and analysts issued on July 11th. Michaël Trabbia, CEO of Orange Belgium: “I look forward to implement our agreement for the benefit of Belgian customers as well as society. This collaboration will enable Orange Belgium to continue to challenge the telecom market, while facilitating a faster and more extensive 5G deployment in Belgium and m

Artefact : Grand Prix du Search 2019: Artefact and SEB doubly rewarded!22.11.2019 17:56:00 CETPress release

Press Release Paris, 22 November 2019 Grand Prix du Search 2019: Artefact and SEB doubly rewarded! Artefact’s “Full Search” strategy ensured optimal search engine placement for Groupe SEB products on Amazon thanks to Data At the Grand Prix du Search 2019 ceremony, Groupe SEB and Artefact won a gold medal in the Retail Search category and a silver medal in the Search & Data category for the efficiency of their eRetail strategy on Amazon. These medals recognize the alliance of Data with the Amazon advertising search solutions which ensure optimal placement of Tefal products on the results pages of the e-commerce giant. Groupe SEB, the world reference in small domestic equipment, is, with its TEFAL brand, an historic leader increasingly challenged on Amazon: +30% new players (vs 2018) in this category. The Amazon online sales platform has become so essential for retailers, it’s a new medium: 50% of online consumers begin their purchase on Amazon1. Product referencing has become a key elem

Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer22.11.2019 17:05:00 CETPress release

First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival in people with unresectable hepatocellular carcinoma compared with sorafenib Results will be presented in the Presidential session at the European Society for Medical Oncology (ESMO) Asia Congress 2019 Basel, 22 November 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will today present positive results from the Phase III IMbrave150 study evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab). The data show statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Tecentriq in combination with Avastin reduced the risk of death (OS) by 42% (hazard ratio [HR]=0.58; 95% CI: 0.42–0.79; p=0.0006) and reduced the risk of disease worsening or death (PFS) by 41% (HR

Conditions for Riksbank Bid Procedures Sek Bonds22.11.2019 16:20:00 CETPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2019-11-28 Maturity date Loan ISIN code Coupon Volume, SEK million 2025-05-12 1058 SE0005676608 2.50 % 500 +/- 250 2029-11-12 1061 SE0011281922 0.75 % 500 +/- 250 Settlement date 2019-12-02 Bids have to be entered by 10.00 on NOV 28, 2019 Highest permitted bid volume: 500 SEK million in issue SGB 1058 and 500 SEK million in issue SGB 1061 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CET) ON NOV 28, 2019. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at

Vostok New Ventures Ltd’s Nomination Committee22.11.2019 16:00:00 CETPress release

Vostok New Ventures Ltd (“Vostok New Ventures”) is pleased to announce the composition of the Nomination Committee for the 2020 Annual General Meeting Stockholm, Nov. 22, 2019 (GLOBE NEWSWIRE) -- The Nomination Committee for the 2020 AGM has been appointed in accordance with the principles resolved by the 2019 AGM. The members of the Nomination Committee are: Jake Hennemuth, appointed by Acacia Partners; Boris Zhilin, appointed by Armor Advisors LLC; Evert Carlsson, appointed by Swedbank Robur Fonder; and Lars O Grönstedt, Chairman of the Board of Directors of Vostok New Ventures. As per the resolution of the 2019 AGM, the task of the Nomination Committee is to make recommendations to the 2020 AGM regarding the following matters: (i) election of the Chairman for the AGM, (ii) election of Directors, (iii) election of the Chairman of the Board of Directors, (iv) remuneration to the Directors, (v) election of the Company’s auditors, (vi) compensation to the Company’s auditors, and (vii) p

Vostok New Ventures Ltd:s valberedning22.11.2019 16:00:00 CETPressemelding

Vostok New Ventures Ltd (”Vostok New Ventures”) får härmed meddela sammansättningen av valberedningen inför årsstämman 2020 Stockholm, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Sammansättningen av valberedningen inför årsstämman 2020 har utsetts i enlighet med beslut av årsstämman 2019. Valberedningen består av följande medlemmar: Jake Hennemuth, utsedd av Acacia Partners; Boris Zhilin, utsedd av Armor Advisors LLC; Evert Carlsson, utsedd av Swedbank Robur Fonder; och Lars O Grönstedt, Styrelseordförande Vostok New Ventures. Enligt beslut av årsstämman 2019 ska valberedningens bereda och lägga fram förslag inför årsstämman 2020 avseende: (i) val av ordförande vid årsstämman, (ii) val av styrelseledamöter, (iii) val av styrelseordförande, (iv) styrelsearvode till ledamöter, (v) val av bolagets revisorer (vi) ersättning till bolagets revisorer, och (vii) Principer för utseende av valberedning inför årsstämman 2021 Aktieägare som önskar lämna förslag till årsstämman avseende ovan angivna frågor k